Advertisement

Principles of Medical Management

  • Tarek Mekhail
  • Rony Abou-Jawde
  • Maurie Markman
Part of the Current Clinical Oncology book series (CCO)

Abstract

In the past, patients rarely questioned the therapeutic decisions made by their physicians. Physicians, in turn, were guided by the principle of “doing onto others as you would have done onto you” and were largely limited by their clinical experiences. Today, evidence-based medicine dictates most treatment decisions, and the role of the physician in educating patients about available therapeutic options is becoming increasingly critical. The patient’s autonomy has taken a more significant role in the ultimate treatment chosen.

Keywords

Chronic Lymphocytic Leukemia Chronic Myeloid Leukemia Acute Promyelocytic Leukemia Acute Myelogenous Leukemia Chronic Myeloid Leukemia Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bos JL. Ras oncogenes in human cancer: a review. Cancer Res 1989; 49:4682–4689.PubMedGoogle Scholar
  2. 2.
    Rabbitts TH. Chromosomal translocations in human cancer. Nature 1994; 372:143–149.PubMedCrossRefGoogle Scholar
  3. 3.
    Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244:707–712.PubMedCrossRefGoogle Scholar
  4. 4.
    Fenaux PC, Chomienne C, Degos L. Acute promyelocytic leukemia: biology and treatment. Semin Oncol 1997; 24:92–102.PubMedGoogle Scholar
  5. 5.
    Stanbridge, EJ. Suppression of malignancy in human cells. Nature 1976; 260:17–20.PubMedCrossRefGoogle Scholar
  6. 6.
    Knudson AG, Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971; 68:820–823.PubMedCrossRefGoogle Scholar
  7. 7.
    Bruce WR. The action of chemotherapeutic agents at the cellular level and the effects of these agents on hematopoietic and lymphomatous tissue. Proc Can Cancer Conf 1967; 7:53–64.PubMedGoogle Scholar
  8. 8.
    Valeriote F van Putten L. Proliferation-dependent cytotoxicity of anticancer agents: a review. Cancer Res 1975; 35:2619–2630.PubMedGoogle Scholar
  9. 9.
    Beck WT. The cell biology of multiple drug resistance. Biochem Pharmacol 1987; 36:2879–2887.PubMedCrossRefGoogle Scholar
  10. 10.
    Moscow JA, Cowan KH. Multidrug resistance. J Natl Cancer Inst 1988; 80:14–20.PubMedCrossRefGoogle Scholar
  11. 11.
    Stone RM, Mayer RJ. The unique aspects of acute promyelocytic leukemia. J Clin Oncol 1990; 8:1913–1921.PubMedGoogle Scholar
  12. 12.
    Warrell RP, Jr, de The H, Wang ZY, Degos L. Acute promyelocytic leukemia. N Engl J Med 1993; 329:177–189.PubMedCrossRefGoogle Scholar
  13. 13.
    Mattei MG, Petkovich M, Mattei JF, Brand N, Chambon P. Mapping of the human retinoic acid receptor to the q21 band of chromosome 17. Hum Genet 1988; 80:186–188.PubMedCrossRefGoogle Scholar
  14. 14.
    Daniel MT, Koken M, Romagne O, et al. PML protein expression in hematopoietic and acute promyelocytic leukemia cells. Blood 1993; 82:1858–1867.PubMedGoogle Scholar
  15. 15.
    Fenaux P, Degos L. Differentiation therapy for acute promyelocytic leukemia. N Engl J Med 1997; 337:1076–1077.PubMedCrossRefGoogle Scholar
  16. 16.
    Tallman MS, Andersen JW, Schiffer CA, et al. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 1997; 337:1021–1028.PubMedCrossRefGoogle Scholar
  17. 17.
    Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344:1031–1037.PubMedCrossRefGoogle Scholar
  18. 18.
    Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344:1038–1042.PubMedCrossRefGoogle Scholar
  19. 19.
    Goldman JM, Melo JV. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344:1084–1086.PubMedCrossRefGoogle Scholar
  20. 20.
    Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001; 344:1052–1056.PubMedCrossRefGoogle Scholar
  21. 21.
    Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256:495–497.PubMedCrossRefGoogle Scholar
  22. 22.
    White CA, Weaver RL, Grillo-Lopez AJ. Antibody-targeted immunotherapy for treatment of malignancy. Annu Rev Med 2001; 52:125–145.PubMedCrossRefGoogle Scholar
  23. 23.
    Weiner LM. An overview of monoclonal antibody therapy of cancer. Semin Oncol 1999; 26:41–50.PubMedGoogle Scholar
  24. 24.
    Hernandez JA. Land KJ, McKenna RW. Leukemias, myeloma, and other lymphoreticular neoplasms. Cancer 1995; 75:381–394.PubMedCrossRefGoogle Scholar
  25. 25.
    Andrews RG, Takahashi M, Segal GM, Powell JS, Bernstein ID, Singer JW. The L4F3 antigen is expressed by unipotent and multipotent colonyforming cells but not by their precursors. Blood 1986; 68:1030–1035.PubMedGoogle Scholar
  26. 26.
    Dinndorf PA, Andrews RG, Benjamin D, Ridgway D, Wolff L, Bernstein ID. Expression of normal myeloid-associated antigens by acute leukemia cells. Blood 1986; 67:1048–1053.PubMedGoogle Scholar
  27. 27.
    Naito K, Takeshita A, Shigeno K, et al. Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines. Leukemia 2000 14:1436–1443.PubMedCrossRefGoogle Scholar
  28. 28.
    Anderson KC, Bates MP, Slaughenhoupt BL, Pinkus GS, Schlossman SF, Nadler LM. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood 1984; 63:1424–1433.PubMedGoogle Scholar
  29. 29.
    Press OW, Appelbaum F, Ledbetter JA, et al. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood 1987; 69:584–591.PubMedGoogle Scholar
  30. 30.
    Einfeld DA, Brown JP, Valentine MA, Clark EA, Ledbetter JA. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J 1988; 7:711–717.PubMedGoogle Scholar
  31. 31.
    Press OW. Radiolabeled antibody therapy of B-cell lymphomas. Semin Oncol 1999; 26:58–65.PubMedGoogle Scholar
  32. 32.
    Dyer MJ. The role of CAMPATH-1 antibodies in the treatment of lymphoid malignancies. Semin Oncol 1999; 26:52–57.PubMedGoogle Scholar
  33. 33.
    Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000; 103211–225.Google Scholar
  34. 34.
    Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783–792.PubMedCrossRefGoogle Scholar
  35. 35.
    Harari D, Yarden Y. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene 2000; 19:6102–6114.PubMedCrossRefGoogle Scholar
  36. 36.
    Waksal HW. Role of an anti-epidermal growth factor receptor in treating cancer. Cancer Metastasis Rev 1999; 18:427–436.PubMedCrossRefGoogle Scholar
  37. 37.
    Ciardiello F, Caputo R, Bianco R, et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 2001; 7:1459–1465.PubMedGoogle Scholar

Copyright information

© Humana Press, Inc., Totowa, NJ 2006

Authors and Affiliations

  • Tarek Mekhail
    • 1
  • Rony Abou-Jawde
    • 2
  • Maurie Markman
    • 3
  1. 1.The Cleveland Clinic FoundationLung Cancer Program, The Cleveland Clinic Taussig Cancer CenterCleveland
  2. 2.The Cleveland Clinic FoundationHematology and Medical Oncology, Taussig Cancer CenterCleveland
  3. 3.University of Texas M. D. Anderson Cancer CenterHouston

Personalised recommendations